Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Larkin

Showing results (31-40 of 130) with videos related to

Pageof 13
Sort By:
Critical Reviews in Oncology/Hematology|July 25, 2006
Kinase inhibitors in the treatment of renal cell carcinomaJames M G Larkin, Tim Eisen
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2007
Potential clinical applications of epothilones: a review of phase II studiesJ M G Larkin, S B Kaye
AORN Journal|August 26, 2021
COVID-19 Response Unites Perioperative Teams at a Recently Merged Health Care SystemBrenda G Larkin, Cindy Mahal-van-Brenk
The Oncologist|November 27, 2009
Combination systemic therapy for advanced renal cell carcinomaRowan E Miller, James M G Larkin
Clinical Medicine Insights. Oncology|November 16, 2011
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanibNaveen S Vasudev, James M G Larkin
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 16, 2005
The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progressJ M G Larkin, M E Gore
Expert Opinion on Pharmacotherapy|August 19, 2017
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignanciesMichael J Flynn, James M G Larkin
Eye (London, England)|July 26, 2014
Sterile postoperative endophthalmitis following HOYA IOL insertionN Kumaran, G Larkin, E J Hollick
Journal of Biomedical Optics|January 7, 2017
Mapping optical path length and image enhancement using quantitative orientation-independent differential interference contrast microscopyMichael Shribak, Kieran G Larkin, David Biggs
British Journal of Cancer|February 3, 2011
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapiesM E Gore, J M G Larkin
Pageof 13

Showing results (31-40 of 130) with videos related to

Sort By:
Pageof 13
Critical Reviews in Oncology/Hematology|July 25, 2006
Kinase inhibitors in the treatment of renal cell carcinomaJames M G Larkin, Tim Eisen
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2007
Potential clinical applications of epothilones: a review of phase II studiesJ M G Larkin, S B Kaye
AORN Journal|August 26, 2021
COVID-19 Response Unites Perioperative Teams at a Recently Merged Health Care SystemBrenda G Larkin, Cindy Mahal-van-Brenk
The Oncologist|November 27, 2009
Combination systemic therapy for advanced renal cell carcinomaRowan E Miller, James M G Larkin
Clinical Medicine Insights. Oncology|November 16, 2011
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanibNaveen S Vasudev, James M G Larkin
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 16, 2005
The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progressJ M G Larkin, M E Gore
Expert Opinion on Pharmacotherapy|August 19, 2017
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignanciesMichael J Flynn, James M G Larkin
Eye (London, England)|July 26, 2014
Sterile postoperative endophthalmitis following HOYA IOL insertionN Kumaran, G Larkin, E J Hollick
Journal of Biomedical Optics|January 7, 2017
Mapping optical path length and image enhancement using quantitative orientation-independent differential interference contrast microscopyMichael Shribak, Kieran G Larkin, David Biggs
British Journal of Cancer|February 3, 2011
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapiesM E Gore, J M G Larkin
Pageof 13